Toll-like receptor modulation: A novel therapeutic strategy in cardiovascular disease?

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 11, 2008, Pages 1329-1346

  Katsargyris, Athanasios ^a   Klonaris, Chris ^a   Bastounis, Elias ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Agonists; Antagonists; Atherosclerosis; Cardiovascular disorders; Coronary artery disease; Heart failure; Immune response; Inflammation; Innate immunity; Ligands; Myocarditis; Toll like receptors; Transgenic mice

Indexed keywords

6 [N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL] 1 CYCLOHEXENE 1 CARBOXYLIC ACID ETHYL ESTER; ATORVASTATIN; CBLB 501; CBLB 502; ERITORAN; FLAGELLIN RECOMBINANT PROTEIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIQUIMOD; LIGAND; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MYELOID DIFFERENTIATION FACTOR 88; OLIVE OIL; POLYUNSATURATED FATTY ACID; RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; RECOMBINANT RECEPTOR; RESARTOVID; RESVERATROL; SIMVASTATIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; CLINICAL TRIAL; DIET THERAPY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; EXPERIMENTAL MOUSE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; INFECTION; INNATE IMMUNITY; INTERVENTION STUDY; LIGAND BINDING; MYOCARDIAL DISEASE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR BLOCKING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SURGICAL INFECTION; VERRUCA VULGARIS;

CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HUMANS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 56249101032     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.11.1329     Document Type: Review

References (220)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138(5 Pt 2):S419-20
2. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21(12):1876-90
3. Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 2005;26(17):1700-4
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352(16):1685-95
5. Vanderlaan PA, Reardon CA. Thematic review series: the immune system and atherogenesis. The unusual suspects: an overview of the minor leukocyte populations in atherosclerosis. J Lipid Res 2005;46(5):829-38
6. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Ann Rev Immunol 2004;22:361-403
7. Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004;34(5):328-34
8. Tobias P, Curtiss LK. Thematic review series: the immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. J Lipid Res 2005;46(3):404-11
9. Curtiss LK, Tobias PS. The toll of Toll-like receptors, especially Toll-like receptor 2, on murine atherosclerosis. Curr Drug Targets 2007;8(12):1230-8
10. Hommels MJ, Kroon AA, Netea MG, et al. The Asp299Gly Toll-like receptor 4 polymorphism in advanced aortic atherosclerosis. Neth J Med 2007;65(6):203-7
11. Li H, Sun B. Toll-like receptor 4 in atherosclerosis. J Cell Mol Med 2007;11(1):88-95
12. Liu X, Ukai T, Yumoto H, et al. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 2008;196(1):146-54
13. Janeway CA Jr, Medzhitov R. Innate immune recognition. Ann Rev Immunol 2002;20:197-216
14. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004;430(6996):257-63
15. O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 2006;18(1):3-9
16. Foldes G, Von Haehling S, Anker SD. Toll-like receptor modulation in cardiovascular disease: a target for intervention? Expert Opin Investig Drugs 2006;15(8):857-71
17. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988;52(2):269-79
18. Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86(6):973-83
19. Divanovic S, Trompette A, Atabani SF, et al. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol 2005;6(6):571-8
20. Takeda K, Kaisho T, Akira S. Toll-like receptors. Ann Rev Immunol 2003;21:335-76
21. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801
22. Ahmad-Nejad P, Hacker H, Rutz M, et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002;32(7):1958-68
23. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science (New York, NY) 2004;303(5663):1526-9
24. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: toll-like receptors in cardiovascular disease. Nat Clin Pract 2007;4(8):444-54
25. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2(8):675-80
26. Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003;16(4):637-46
27. Takeuchi O, Sato S, Horiuchi T, et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002;169(1):10-4
28. Werts C, Tapping RI, Mathison JC, et al. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol 2001;2(4):346-52
29. Means TK, Wang S, Lien E, et al. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999;163(7):3920-7
30. Shimizu T, Kida Y, Kuwano K. Ureaplasma parvum lipoproteins, including MB antigen, activate NF-κB through TLR1, TLR2 and TLR6. Microbiology 2008;154(Pt 5):1318-25
31. Henneke P, Dramsi S, Mancuso G, et al. Lipoproteins are critical TLR2 activating toxins in group B streptococcal sepsis. J Immunol 2008;180(9):6149-58
32. Schwandner R, Dziarski R, Wesche H, et al. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999;274(25):17406-9
33. Knapp S, Von Aulock S, Leendertse M, et al. Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol 2008;180(5):3478-84
34. Ozinsky A, Underhill DM, Fontenot JD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000;97(25):13766-71
35. Zahringer U, Lindner B, Inamura S, et al. TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 2008;213(3-4):205-24
36. Hajjar AM, O'Mahony DS, Ozinsky A, et al. Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol 2001;166(1):15-9
37. Ray A, Biswas T. Porin of Shigella dysenteriae enhances Toll-like receptors 2 and 6 of mouse peritoneal B-2 cells and induces the expression of immunoglobulin M, immunoglobulin G2a and immunoglobulin A. Immunology 2005;114(1):94-100
38. Burke JM, Ganley-Leal LM, Khatri A, Wetzler LM. Neisseria meningitidis PorB, a TLR2 ligand, induces an antigen-specific eosinophil recall response: potential adjuvant for helminth vaccines? J Immunol 2007;179(5):3222-30
39. Bieback K, Lien E, Klagge IM, et al. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol 2002;76(17):8729-36
40. Zhao Y, Yokota K, Ayada K, et al. Helicobacter pylori heat-shock protein 60 induces interleukin-8 via a Toll-like receptor (TLR)2 and mitogen-activated protein (MAP) kinase pathway in human monocytes. J Med Microbiol 2007;56(Pt 2):154-64
41. Li M, Carpio DF, Zheng Y, et al. An essential role of the NF-kappa B/ Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001;166(12):7128-35
42. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282(5396):2085-8
43. Hoshino K, Kaisho T, Iwabe T, et al. Differential involvement of IFN-β in Toll-like receptor-stimulated dendritic cell activation. Int Immunol 2002;14(10):1225-31
44. Qureshi ST, Lariviere L, Leveque G, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999;189(4):615-25
45. Necela BM, Su W, Thompson EA. Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor γ and nuclear factor-κB in macrophages. Immunology 2008
46. Takeuchi O, Hoshino K, Kawai T, et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999;11(4):443-51
47. Dessing MC, Schouten M, Draing C, et al. Role played by Toll-like receptors 2 and 4 in lipoteichoic acid-induced lung inflammation and coagulation. J Infect Dis 2008;197(2):245-52
48. Seo HS, Michalek SM, Nahm MH. Lipoteichoic acid is important in innate immune responses to Gram-positive bacteria. Infect Immun 2008;76(1):206-13
49. Kawasaki K, Akashi S, Shimazu R, et al. Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 2000;275(4):2251-4
50. Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 2002;23(11):509-12
51. Zou N, Ao L, Cleveland JC Jr, et al. Critical role of extracellular heat shock cognate protein 70 in the myocardial inflammatory response and cardiac dysfunction after global ischemia-reperfusion. Am J Physiol 2008;294(6):H2805-13
52. Lehnardt S, Schott E, Trimbuch T, et al. A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS. J Neurosci 2008;28(10):2320-31
53. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000;1(5):398-401
54. Awomoyi AA, Rallabhandi P, Pollin TI, et al. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol 2007;179(5):3171-7
55. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195(1):99-111
56. Kuhns DB, Priel DA, Gallin JI. Induction of human monocyte interleukin (IL)-8 by fibrinogen through the toll-like receptor pathway. Inflammation 2007;30(5):178-88
57. Schoneveld AH, Hoefer I, Sluijter JP, et al. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis 2008;197(1):95-104
58. Gondokaryono SP, Ushio H, Niyonsaba F, et al. The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol 2007;82(3):657-65
59. Smith MF JR, Novotny J, Carl VS, Comeau LD. Helicobacter pylori and toll-like receptor agonists induce syndecan-4 expression in an NF-κB-dependent manner. Glycobiology 2006;16(3):221-9
60. Miller YI, Viriyakosol S, Binder CJ, et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003;278(3):1561-8
61. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science (New York, NY) 2002;298(5595):1025-9
62. Sheng KC, Pouniotis DS, Wright MD, et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 2006;118(3):372-83
63. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408(6813):740-5
64. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413(6857):732-8
65. Liu L, Botos I, Wang Y, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science (New York, NY) 2008;320(5874):379-81
66. Forsbach A, Nemorin JG, Montino C, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 2008;180(6):3729-38
67. Hattermann K, Picard S, Borgeat M, et al. The Toll-like receptor 7/ 8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. FASEB J 2007;21(7):1575-85
68. Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev 2008;60(7):813-23
69. Gantier MP, Tong S, Behlke MA, et al. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J Immunol 2008;180(4):2117-24
70. Dan JM, Wang JP, Lee CK, Levitz SM. Cooperative stimulation of dendritic cells by Cryptococcus neoformans mannoproteins and CpG oligodeoxynucleotides. PLoS One 2008;3(4):e2046. Published online 30 April 2008, doi:10.1371/journal. pone.0002046
71. Haas T, Metzger J, Schmitz F, et al. The DNA sugar backbone 2′ deoxyribose determines toll-like receptor 9 activation. Immunity 2008;28(3):315-23
72. Coban C, Ishii KJ, Kawai T, et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med 2005;201(1):19-25
73. Parroche P, Lauw FN, Goutagny N, et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA 2007;104(6):1919-24
74. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416(6881):603-7
75. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410(6832):1099-103
76. Galkin VE, Yu X, Bielnicki J, et al. Divergence of quaternary structures among bacterial flagellar filaments. Science (New York, NY) 2008;320(5874):382-5
77. Palazzo M, Gariboldi S, Zanobbio L, et al. Cross-talk among Toll-like receptors and their ligands. Int Immunol 2008;20(5):709-18
78. Zhang D, Zhang G, Hayden MS, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science (New York, NY) 2004;303(5663):1522-6
79. Plattner F, Yarovinsky F, Romero S, et al. Toxoplasma profilin is essential for host cell invasion and TLR11-dependent induction of an interleukin-12 response. Cell Host Microbe 2008;3(2):77-87
80. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001;167(5):2887-94
81. Walton KA, Hsieh X, Gharavi N, et al. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem 2003;278(32):29661-6
82. Heine H, Lien E. Toll-like receptors and their function in innate and adaptive immunity. Int Arch Allergy Immunol 2003;130(3):180-92
83. Walton KA, Gugiu BG, Thomas M, et al. A role for neutral sphingomyelinase activation in the inhibition of LPS action by phospholipid oxidation products. J Lipid Res 2006;47(9):1967-74
84. Erridge C, Kennedy S, Spickett CM, Webb DJ. Oxidised phospholipid inhibition of toll-like receptor (TLR) signalling is restricted to TLR2 and TLR4 - roles for CD14, LPS-binding protein and MD2 as targets for specificity of inhibition. J Biol Chem 2008;283(36):24748-59
85. Vabulas RM, Ahmad-Nejad P, Da Costa C, et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001;276(33):31332-9
86. Gao B, Tsan MF. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor α release by murine macrophages. J Biol Chem 2003;278(1):174-9
87. Bausinger H, Lipsker D, Ziylan U, et al. Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur J immunol 2002;32(12):3708-13
88. Ye Z, Gan YH. Flagellin contamination of recombinant heat shock protein 70 is responsible for its activity on T cells. J Biol Chem 2007;282(7):4479-84
89. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;276(13):10229-33
90. Scheibner KA, Lutz MA, Boodoo S, et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006;177(2):1272-81
91. Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear factor κB by oxidative stress in cardiac myocytes. J Biol Chem 2001;276(7):5197-203
92. Johnson GB, Brunn GJ, Tang AH, Platt JL. Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol 2003;24(1):19-24
93. Matzinger P. The danger model: a renewed sense of self. Science (New York, NY) 2002;296(5566):301-5
94. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system of dying cells. Nature 2003;425(6957):516-21
95. Bauters C, Marotte F, Hamon M, et al. Accumulation of fetal fibronectin mRNAs after balloon denudation of rabbit arteries. Circulation 1995;92(4):904-11
96. Vink A, De Kleijn DP, Pasterkamp G. Functional role for toll-like receptors in atherosclerosis and arterial remodeling. Curt Opin Lipidol 2004;15(5):515-21
97. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006;117(5):979-87; quiz 88
98. Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998;2(2):253-8
99. Frantz S, Kobzik L, Kim YD, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and falling myocardium. J Clin Invest 1999;104(3):271-80
100. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004;5(10):975-9
101. Yamamoto M, Sato S, Hemmi H, et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003;4(11):1144-50
102. Bin LH, Xu LG, Shu HB. TIRP, a novel Toll/interleukin-1 receptor (TIR) domain-containing adapter protein involved in TIR signaling. J Biol Chem 2003;278(27):24526-32
103. Harari OA, Alcaide P, Ahl D, et al. Absence of TRAM restricts Toll-like receptor 4 signaling in vascular endothelial cells to the MyD88 pathway. Circ Res 2006;98(9):1134-40
104. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002;105(10):1158-61
105. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104(25):3103-8
106. Mullick AE, Soldau K, Kiosses WB, et al. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J Exp Med 2008;205(2):373-83
107. Shinohara M, Hirata K, Yamashita T, et al. Local overexpression of toll-like receptors at the vessel wall induces atherosclerotic lesion formation: synergism of TLR2 and TLR4. Arterioscler Thromb Vasc Biol 2007;27(11):2384-91
108. Libby P. Inflammation in atherosclerosis. Nature 2002;420(6917):868-74
109. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in sortie lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 1993;13(10):1501-4
110. Hendrix MG, Salimans MM, Van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990;136(1):23-8
111. Kozarov EV, Dorn BR, Shelburne CE, et al. Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Arterioscler Thromb Vasc Biol 2005;25(3):e17-8
112. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2(8618):983-6
113. Adam E, Melnick JL, Probtsfield JL, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987;2(8554):291-3
114. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002;359(9301):133-5
115. Ishizaka N, Ishizaka Y, Takahashi E, et al. Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers. Circulation 2002;105(9):1028-30
116. Moazed TC, Campbell LA, Rosenfeld ME, et al. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999;180(1):238-41
117. Liu L, Hu H, Ji H, et al. Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months. Mol Cell Biochem 2000;215(1-2):123-8
118. Hsich E, Zhou YF, Paigen B, et al. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis 2001;156(1):23-8
119. Vliegen I, Duijvestijn A, Stassen F, Bruggeman C. Murine cytomegalovirus infection directs macrophage differentiation into a pro-inflammatory immune phenotype: implications for atherogenesis. Microbes Infect 2004;6(12):1056-62
120. Vliegen I, Duijvestijn A, Grauls G, et al. Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation. Microbes Infect 2004;6(1):17-24
121. Lalla E, Lamster IB, Hofmann MA, et al. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2003;23(8):1405-11
122. Gibson FC, 3rd, Ukai T, Genco CA. Engagement of specific innate immune signaling pathways during Porphyromonas gingivalis induced chronic inflammation and atherosclerosis. Front Biosci 2008;13:2041-59
123. Miyamoto T, Yumoto H, Takahashi Y, et al. Pathogen-accelerated atherosclerosis occurs early after exposure and can be prevented via immunization. Infect Immun 2006;74(2):1376-80
124. Fabricant CG, Fabricant J. Atherosclerosis induced by infection with Marek's disease herpesvirus in chickens. Am Heart J 1999;138(5 Pt 2):S465-8
125. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosderosis. Circulation 2002;105(1):15-21
126. Bjorkbacka H. Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr Opin Lipidol 2006;17(5):527-33
127. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25(2):187-91
128. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347(3):185-92
129. Ameziane N, Beillat T, Verpillat P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003;23(12):e61-4
130. Boekholdt SM, Agema WR, Peters RJ, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003;107(19):2416-21
131. Vainas T, Stassen FR, Bruggeman CA, et al. Synergistic effect of Toll-like receptor 4 and CD14 polymorphisms on the total atherosclerosis burden in patients with peripheral arterial disease. J Vasc Surg 2006;44(2):326-32
132. Hamann L, Gomma A, Schroder NW, et al. A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. J Mol Med (Berlin, Germany) 2005;83(6):478-85
133. Labrum R, Bevan S, Sitzer M, et al. Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke 2007;38(4):1179-84
134. Norata GD, Garlaschelli K, Ongari M, et al. Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J Intern Med 2005;258(1):21-7
135. Zee RY, Hegener HH, Gould J, Ridker PM. Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis. Stroke 2005;36(1):154-7
136. Netea MG, Hijmans A, Van Wissen S, et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur J Clin Invest 2004;34(2):94-9
137. Yang IA, Holloway JW, Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis 2003;170(1):187-90
138. Calvano JE, Bowers DJ, Coyle SM, et al. Response to systemic endotoxemia among humans bearing polymorphisms of the Toll-like receptor 4 (hTLR4). Clin Immunol (Orlando, Fla) 2006;121(2):186-90
139. Kumpf O, Hamann L, Schlag PM, Schumann RR. Pre- and postoperative cytokine release after in vitro whole blood lipopolysaccharide stimulation and frequent toll-like receptor 4 polymorphisms. Shock (Augusta, GA) 2006;25(2):123-8
140. Edfeldt K, Bennet AM, Eriksson P, et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004;25(16):1447-53
141. Lin YC, Chang YM, Yu JM, et al. Toll-like receptor 4 gene C119A but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. Atherosclerosis 2005;180(2):305-9
142. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004;10(4):416-21
143. Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004;101(29):10679-84
144. Hollestelle SC, De Vries MR, Van Keulen JK, et al. Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 2004;109(3):393-8
145. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005;115(11):3149-56
146. Shishido T, Nozaki N, Takahashi H, et al. Central role of endogenous Toll-like receptor-2 activation in regulating inflammation, reactive oxygen species production, and subsequent neointimal formation after vascular injury. Biochem Biophys Res Commun 2006;345(4):1446-53
147. Cao F, Castrillo A, Tontonoz P, et al. Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect Immun 2007;75(2):753-9
148. Shiraki R, Inoue N, Kobayashi S, et al. Toll-like receptor 4 expressions on peripheral blood monocytes were enhanced in coronary artery disease even in patients with low C-reactive protein. Life Sci 2006;80(1):59-66
149. Methe H, Kim JO, Kofler S, et al. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005;111(20):2654-61
150. Satoh M, Shimoda Y, Maesawa C, et al. Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int J Cardiol 2006;109(2):226-34
151. Devaraj S, Dasu MR, Rockwood J, et al. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008;93(2):578-83
152. Thomas JA, Haudek SB, Koroglu T, et al. IRAK1 deletion disrupts cardiac Toll/IL-1 signaling and protects against contractile dysfunction. Am J Physiol 2003;285(2):H597-606
153. Nemoto S, Vallejo JG, Knuefermann P, et al. Escherichia coli LPS-induced LV dysfunction: role of Toll-like receptor-4 in the adult heart. Am J Physiol 2002;282(6):H2316-23
154. Knuefermann P, Sakata Y, Baker JS, et al. Toll-like receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart. Circulation 2004;110(24):3693-8
155. Satoh M, Nakamura M, Akatsu T, et al. Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis. Clin Sci (Lond) 2003;104(6):577-84
156. Marty RR, Dirnhofer S, Mauermann N, et al. MyD88 signaling controls autoimmune myocarditis induction. Circulation 2006;113(2):258-65
157. Triantafilou K, Orthopoulos G, Vakakis E, et al. Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol 2005;7(8):1117-26
158. Birks EJ, Felkin LE, Banner NR, et al. Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant 2004;23(2):228-35
159. Shishido T, Nozaki N, Yamaguchi S, et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003;108(23):2905-10
160. Ha T, Li Y, Hua F, et al. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 2005;68(2):224-34
161. Chong AJ, Shimamoto A, Hampton CR, et al. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 2004;128(2):170-9
162. Oyama J, Blais C JR, Liu X, et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004;109(6):784-9
163. Nozaki N, Shishido T, Takeishi Y, Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 2004;110(18):2869-74
164. Dunzendorfer S, Lee HK, Tobias PS. Flow-dependent regulation of endothelial Toll-like receptor 2 expression through inhibition of SP1 activity. Circ Res 2004;95(7):684-91
165. Erridge C. The roles of pathogen-associated molecular patterns in atherosclerosis. Trends Cardiovasc Med 2008;18(2):52-6
166. Mizoguchi E, Orihara K, Hamasaki S, et al. Association between Toll-like receptors and the extent and severity of coronary artery disease in patients with stable angina. Coron Artery Dis 2007;18(1):31-8
167. Castrillo A, Joseph SB, Vaidya SA, et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003;12(4):805-16
168. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004;16(1):3-9
169. Rice JB, Stoll LL, Li WG, et al. Low-level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. Arterioscler Thromb Vasc Biol 2003;23(9):1576-82
170. Ott SJ, El Mokhtari NE, Musfeldt M, et al. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 2006;113(7):929-37
171. Liu C, Waters DD. Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trials. Prog Cardiovasc Dis 2005;47(4):230-9
172. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke 2002;33(11):2581-6
173. Vender RB, Goldberg O. Innovative uses of imiquimod. J Drugs Dermatol 2005;4(1):58-63
174. Gupta AK, Cherman AM, Tyring SK. Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg 2004;8(5):338-52
175. Gearing AJ. Targeting toll-like receptors for drug development: a summary of commercial approaches. Immunol Cell Biol 2007;85(6):490-4
176. LeBouder E, Rey-Nores JE, Rushmere NK, et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003;171(12):6680-9
177. Qin J, Qian Y, Yao J, et al. SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem 2005;280(26):25233-41
178. Johnson BJ, Le TT, Dobbin CA, et al. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J Biol Chem 2005;280(6):4037-47
179. Loiarro M, Capolunghi F, Fanto N, et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol 2007;82(4):801-10
180. Jiang Z, Georgel P, Li C, et al. Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis. Proc Natl Acad Sci USA 2006;103(29):10961-6
181. Loiarro M, Sette C, Gallo G, et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-κB. J Biol Chem 2005;280(16):15809-14
182. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev 2007;7(5):353-64
183. Lynn M, Wong YN, Wheeler JL, et al. Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]. J Pharmacol Exp Ther 2004;308(1):175-81
184. Rossignol DP, Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res 2002;8(6):483-8
185. Wong YN, Rossignol D, Rose JR, et al. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol 2003;43(7):735-42
186. Shimamoto A, Chong AJ, Yada M, et al. Inhibition of Toll-like receptor 4
187. Rossignol DP, Wasan KM, Choo E, et al. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother 2004;48(9):3233-40
188. Lynn M, Rossignol DP, Wheeler JL, et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003;187(4):631-9
189. Bennett-Guerrero E, Grocott HP, Levy JH, et al. A Phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg 2007;104(2):378-83
190. Wasan KM, Risovic V, Sivak O, et al. Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits. Pharm Res 2008;25(1):176-82
191. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007;56(9):2957-67
192. Kaplan BI, Tipirneni P. Lessons for the future: a review of sepsis past and present. IDrugs 2007;10(4):264-9
193. Yamada M, Ichikawa T, Ii M, et al. Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl) cyclohex-1-ene-1-carboxylate. J Med Chem 2005;48(23):7457-67
194. Kawamoto T, Ii M, Kitazaki T, et al. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol 2008;584(1):40-8
195. Takeuchi O, Hoshino K, Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000;165(10):5392-6
196. Heit A, Maurer T, Hochrein H, et al. Cutting edge: toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J Immunol 2003;170(6):2802-5
197. Sacre SM, Andreakos E, Kiriakidis S, et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 2007;170(2):518-25
198. Buwitt-Beckmann U, Heine H, Wiesmuller KH, et al. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 2005;35(1):282-9
199. Cluff CW, Baldridge JR, Stover AG, et al. Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 2005;73(5):3044-52
200. Hawkins LD, Ishizaka ST, McGuinness P, et al. A novel class of endotoxin receptor agonists with simplified structure, Toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J Pharmacol Exp Ther 2002;300(2):655-61
201. Lehr HA, Sagban TA, Ihling C, et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001;104(8):914-20
202. Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005;42(3):724-31
203. Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis 2001;184(2):196-200
204. Pashenkov M, Goess G, Wagner C, et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006;24(36):5716-24
205. Wickelgren I. Immunology. Targeting the tolls. Science (New York, NY) 2006;312(5771):184-7
206. Sung JJ, Lik-Yuen H. HBV-ISS (Dynavax). Curr Opin Mol Ther 2006;8(2):150-5
207. Thompson KA, Strayer DR, Salvato PD, et al. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyl:polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis 1996;15(7):580-7
208. Strayer DR, Carter WA, Brodsky I, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I). poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18(Suppl 1):S88-95
209. Testerman TL, Gerster JF, Imbertson LM, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leuk Biol 1995;58(3):365-72
210. Krieg AM, Efler SM, Wittpoth M, et al. Induction of systemic TH1-like innate Immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004;27(6):460-71
211. Sterpetti AV, Cucina A, Lepidi S, et al. Formation of myointimal hyperplasia and cytokine production in experimental vein grafts. Surgery 1998;123(4):461-9
212. Faries PL, Marin ML, Veith FJ, et al. Immunolocalization and temporal distribution of cytokine expression during the development of vein graft intimal hyperplasia in an experimental model. J Vasc Surg 1996;24(3):463-71
213. Ozaki CK. Cytokines and the early vein graft: strategies to enhance durability. J Vasc Surg 2007;45(Suppl A):A92-8
214. + monocytes. Arterioscler Thromb Vasc Biol 2005;25(7):1439-45
215. Holloway JW, Yang IA, Ye S. Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genomics 2005;15(1):15-21
216. Abe M, Matsuda M, Kobayashi H, et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/ IFN-β pathway in macrophages. Arterioscler Thromb Vasc Biol 2008;28(5):871-7
217. Lee JY, Zhao L, Youn HS, et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 2004;279(17):16971-9
218. Leite MS, Pacheco P, Gomes RN, et al. Mechanisms of increased survival after lipopolysaccharide-induced endotoxic shock in mice consuming olive oil-enriched diet. Shock (Augusta, GA) 2005;23(2):173-8
219. Youn HS, Lee JY, Fitzgerald KA, et al. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 2005;175(5):3339-46
220. Griffiths EA, Duffy LC, Schanbacher FL, et al. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci 2004;49(4):579-89